| Cat.No. | Name | Information |
|---|---|---|
| M13662 | GCN2-IN-1 | GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay. |
| M13661 | GCN2iB | GCN2iB is an ATP-competitive inhibitor of a serine/threonine-protein kinase general control nonderepressible 2 (GCN2), with an IC50 of 2.4 nM. |
| M13425 | Zotatifin | Zotatifin is a first-in-class, sequentially selective inhibitor of RNA helicase eIF4A1. |
| M9260 | SBI-0640756 | SBI-0640756 is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. |
| M2361 | 4EGI-1 | 4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. |
| M2360 | 4E1RCat | 4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM. |
| M40816 | DNL343 | DNL343 is an orally active, as well as CNS-permeable, eIF2B agonist for studies related to amyotrophic lateral sclerosis (ALS). |
| M29546 | CMLD012612 | CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity. |
| M29296 | 2BAct | 2BAct is a highly selective, and orally active eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct is able to penetrate the central nervous system (CNS). 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
